Clonidine is a partial agonist at brain ␣ 2 -adrenoceptors ( ␣ 2 AR), but also has high affinity (K D ϭ 51 nM) in homogenate binding assays for non-adrenergic imidazolinebinding sites (I-sites; imidazoline receptors
Clonidine is the prototypic imidazoline compound that can elicit a diversity of CNS effects (Buccafusco 1992) . Originally thought to be a selective agonist for ␣ 2 -adrenoceptors ( ␣ 2 AR), clonidine is now realized to possesses only slightly lower affinity for non-adrenergic imidazoline receptors (IR) compared to ␣ 2 AR (Bousquet et al. 1984; Ernsberger et al. 1987) .
The first subtype of IR (IR 1 ) was discovered by comparing the hypotensive effects of clonidine to other non-imidazoline ␣ 2 AR agonists, which were far less hypotensive agents than clonidine when micro-injected into the rostral ventrolateral medulla (RVLM) of anesthetized rats (Bousquet et al. 1984) . In those studies, the pharmacological control of blood pressure was found to best correlate with agents classified as imidazoline compounds (Ernsberger and Haxhiu 1997) . In fact, the recommended therapeutic doses for clonidine and other imidazoline compounds to treat patients with hypertension have been positively correlated with their affinities for non-adrenergic imidazoline binding sites (of the I 1 subtype)-whereas no such correlation exists with their affinities for ␣ 2 AR (Buccafusco et al. 1995) .
In psychiatry, novel imidazoline compounds are currently being explored for possible neuro-protective properties , for treating drug withdrawal symptoms (Vandergriff et al. 1999) , and as possible antidepressants (Raddatz and Lanier 1997) . Second-generation imidazoline anti-hypertensives are also now available, which include rilmenidine and moxonidine (Molderings 1997) . Rilmenidine and moxonidine possess approximately 5-fold and 100-fold selective affinities, respectively, for I 1 over ␣ 2 AR sites (Ernsberger et al. 1995a; Piletz et al. 1996) , and this affinity difference probably explains their diminished sedative side-effects relative to clonidine (van Zwieten 1997) .
Like most receptor families, there are several IR subtypes identified using radioligand binding techniques. I 1 sites have high affinity and I 2 sites have low affinity for clonidine (Michel and Ernsberger 1992) . By contrast, planar imidazoline compounds, like idazoxan, exhibit preferential affinity for I 2 sites, of which there are two subclasses: I 2A and I 2B (Eglen et al. 1998) . There are at least two other I-site subtypes defined by various other imidazolines: a cirazoline-sensitive I-site in kidney and brain (Angel et al. 1995 ) and a novel efaroxan-sensitive I-site in pancreas (Monks et al. 1999) . In addition, the search for endogenous ligands has identified two putative IR neurotransmitters: a decarboxylated metabolite of arginine, agmatine , and a ␤ -carboline, harmane (Hudson et al. 1999) .
Only (Piletz et al. 2000b 
MATERIALS AND METHODS

Human Tissue Collection
Discarded brain tissues from five subjects (three males and two females) who died of sudden natural or accidental causes were collected at the time of autopsy at the Cuyahoga County Coroner's Office, Ohio, in accordance with an approved Institutional Review Board protocol. Tissues were coded to protect the identity of subjects. Deaths occurred within four hours of injury. Causes of death were determined by the county medical examiner. Four of the subjects died of cardiovascular failure and one died of asphyxiation secondary to smoke inhalation. The average age of the subjects was 52 Ϯ 10 yr (age range ϭ 24 to 80 yr). All cadavers were refrigerated prior to autopsy, immediately upon arrival at the coroner's facility. The average postmortem interval (from death to freezing of brain tissue) was 16 Ϯ 3 h (range 6 to 21 h). The coroner performed toxicological screens for 50 compounds in the blood, bile, urine, and/ or vitreous fluids of cadavers to identify numerous psychoactive and other compounds. Four of the subjects had no detectable drugs in the toxicological screen. One subject had evidence of lidocaine in the blood. Postmortem autopsies revealed no record of neurological or psychiatric histories for any of the subjects.
At autopsy, blocks of brain tissue were dissected. The techniques for dissection of blocks of tissue have been published for frontal cortex (Brodmann's area 10) and hippocampus (Klimek et al. 1999) , and for locus coeruleus (Klimek et al. 1997) . The tissue block containing the hypothalamus was dissected just anterior to the substantia nigra and was sectioned in the coronal plane. A block of tissue containing the medulla was obtained by a transverse cut just caudal to the caudal end of the locus coeruleus, and this block of tissue was cut in the transverse plane, perpendicular to the rostro-caudal axis of the medulla. Tissue blocks were dipped in 2-methylbutane cooled on dry ice ( Ϫ 50 Њ C), placed on powdered dry ice for 10 min, and then stored in an ultra-cold freezer ( Ϫ 82 Њ C) until sectioned. Frozen blocks of brain tissue were mounted on a specimen chuck of a cryostat microtome (Cryocut 1800, Leica, Reichert-Jung, Deerfield, IL) and tissue sections (20 m thick) were cut at Ϫ 16 Њ C and thaw-mounted onto gelatin-coated microscope slides. Sections were dried under refrigeration and stored at Ϫ 82 Њ C until assayed. (pH 7.4) . This was performed by placing a small drop of reaction buffer containing the radioligand, directly on each slide-mounted section, and then incubating 1 h in a humidity chamber at 22 Њ C. Unbound radioligand was removed by three consecutive washes (1 min each) of the slides in ice-cold reaction buffer, then dipped for 1 sec in ice cold water to remove buffer salts. Slide-mounted sections were dried immediately afterwards under a stream of air at room temperature overnight. Slides were apposed, along with brain-mash calibrated 3 H standards (American Radiolabeled Chemicals Inc., St. Louis, Mo.), to Hyperfilm-3 H (Amersham, Arlington Hts, IL) in x-ray cassettes and stored at room temperature for four weeks. Films were processed with GBX developer and fixer (Eastman Kodak Co., Rochester, NY). The same sections were then stained with cresyl violet to identify anatomical structures. The resulting autoradiograms were quantified using the M2 Microcomputer Imaging Device (Imaging Research, St. Catharines, Ontario, Canada). Hippocampal fields (Klimek et al. 1999) were outlined based on morphological criteria (Duvernoy 1988) . Brainstem and medullary regions were identified with the aid of an atlas (Paxinos and Huang 1995) .
Quantitative Autoradiography
Total binding was determined by incubating sections with 50 nM [ (Piletz et al. 1996) . The percentage of total binding that was specific binding (including I-sites and ␣ 2 AR) was 72 Ϯ 1 % (means Ϯ S.E.M. of all brain regions from all subjects). Of this specific binding, 54 Ϯ 1% was binding to I-sites and 46 Ϯ 1% was binding to ␣ 2 AR.
Competition curves were generated from slide wipes using ligand concentrations from 10 Ϫ10 to 10 Ϫ4 M (11 points in triplicate for each of 3-4 subjects). The measurements were made on serial adjacent caudate sections (2-4 sections per slide, wiped together). After incubation for 1 h and a rapid cold water dip, the caudate sections were wiped from the slides onto S&S #32 glass fiber filters (Schleicher and Schuell, Keene, NH). Radioactivity was measured by liquid scintillation counting. In a typical experiment, total radioactivity remaining in the presence of 60 M NE was 1503 Ϯ 222 cpm, and that remaining in the presence of 20 M cirazoline plus 60 M NE was 433 Ϯ 28 cpm. Competition curves were analyzed by both LIGAND (McPherson 1985) and Prism (GraphPad, San Diego, CA), producing similar results. Data were modeled to one-site and two-site fits (McPherson 1985 ) and the preferred model was chosen by an F test. IC 50 values were computed from 2-3 experiments and were expressed as mean Ϯ SEM.
Drugs
[ 3 H]-clonidine (66.5 Ci/mmol) was purchased from NEN TM (Life Science Products, Inc., Boston, MA) and stored at Ϫ20ЊC before reconstitution in reaction buffer (defined below). Moxonidine and BDF6143 were gifts of Lilly Forschung GmbH Company (Hamburg, Germany). Tizanidine was a gift of Sandoz Pharmaceuticals (Tokyo, Japan). Efaroxan was a gift from Pierre Fabre Pharmacie (Castres Cedex, France). Cirazoline and RX821002 (MIDX; methoxy-idazoxan) were purchased from Research Biochemicals International (Natick, MA). Agmatine, harmane, NE, oxymetazoline, and idazoxan (IDX) were from Sigma Chemical Company (St. Louis, MO). All chemicals were of the highest grade available. Drug solutions were made fresh daily before each experiment. Drug stock solutions were prepared (0.01 M) in either distilled water or 10 mM acetic acid depending on their solubilities and were serially diluted in the reaction buffer.
Technical Note
Several differences are noteworthy comparing our method to the autoradiographic method of De Vos and coworkers (1994): 1) The concentration of [ based on earlier binding studies (Piletz et al. 1991 Figure 2 ).
Despite the overall correlation between the densities of ␣ 2 AR and I-sites (Figure 2 ), there were distinct subregional differences in the distributions of ␣ 2 AR and I-sites in the brain. Highest binding to I-sites was in the principle nucleus of the inferior olive (130 Ϯ 18 fmol/ mg protein) wherein the amount of binding was 10-fold higher than that in the white matter of the prefrontal cortex (Table 1, Figure 2 ). Other areas of high density for [ 3 H]-clonidine binding to I-sites included the polymorphic layer of the hippocampus, dorsal and median raphe, dentate gyrus, hypothalamus, locus coeruleus, central gray, and the hypoglossal nucleus (Table 1) To further illustrate the distinction between ␣ 2 AR and I-sites, quantitative transepts were drawn through specific binding images of hippocampi using an image analysis system ( Figure 3 ). Amounts of binding across a transept through a subregion may differ from the levels outlined in the entire subregion (i.e., data in Table 1 ). In the outlining method (Table 1) Figures 3 and 4 . The difference between these sites was most obvious in the molecular layer of CA1. There, binding to ␣ 2 AR clearly exceeded that of I-sites by 4:1, whereas in other subregions of the hippocampus the ratios of ␣ 2 AR:I sites were closer to 1:1.
To rule out the possibility that the agonist-induced state of ␣ 2 AR might in some way account for brain Isites (e.g., an artifact of using the agonists, [ 3 H]-clonidine and NE), we defined ␣ 2 AR with either NE (60 M) or the ␣ 2 AR antagonist, MIDX (12.5 M). MIDX is a selective antagonist for ␣ 2 AR with very low affinity for the human brain I-sites (IC 50 at I-sites у 60 M) (De Vos et al. 1994; Flamez et al. 1997) . We observed that specific binding to ␣ 2 AR was only slightly greater using MIDX, and the specific binding to I-sites was only slightly lower using MIDX compared to the results with NE. Furthermore, the relative distributions of binding to ␣ 2 AR and I-sites were identical using either of these competitors (Figure 4 , Panel C). The near identity of these results with either displacing agent makes it highly unlikely that an ␣ 2 AR affinity state could account for I-sites.
Competition curves were next generated for [ (1994) . The head of the caudate was chosen for these studies because of the availability of tissue. Five compounds were capable of completely displacing [ 3 H]-clonidine from caudate I-sites, but these mostly had shallow competition curves ( Figure 5 ). The only exception was the ␤-carboline, harmane, which exhibited a monophasic competition curve ( Figure 5 ). The rank order of IC 50 values for I-sites (generated using a single site model) was as follows: cirazoline Ͼ harmane Ͼ BDF6143 Ͼ idazoxan ϭ tizanidine. Agmatine, efaroxan, moxonidine, NE, and Table 2 ).
For comparative purposes, Table 2 shows our Ki values beside those previously determined by De Vos and colleagues (1994) , who also used the head of the human caudate for competition binding studies. The rank-order for human I 1 sites in homogenate binding assays is known to be moxonidine у oxymetazoline Ͼ tizanidine у agmatine у efaroxan ϭ clonidine Ͼ cirazoline Ͼ BDF6143 ϾϾ idazoxan ϾϾ NE (Piletz et al. 1996) . The rank-order for human I 2 sites in homogenate binding assays is cirazoline Ͼ idazoxan ϾϾ oxymetzoline Ͼ moxonidine у efaroxan Ͼ clonidine (Piletz and Sletten 1993) . Thus, the I-site(s) under study has(have) a unique pharmacological profile.
Moxonidine, a compound with preferential I 1 affinity, was found to have low affinity in caudate sections for I-sites labeled by [ Table 2 ). To examine this further, moxonidine was used in parallel with cirazoline to define non-adrenergic binding of [ adrenergic hypotensive effects of clonidine, moxonidine, and rilmenidine (Chan et al. 1996) . Table 3 shows four conditions of [ (Table 3) . Even in the RVLM (Figure 1 , arrow), [ 3 H]-clonidine binding was not substantially more displaced by moxonidine than NE (Table 3) .
DISCUSSION
In the present study, the distributions of [ (Table 1) . This is noteworthy because the RVLM is the site of the anti-hypertensive action ascribed to IR 1 stimulation when imidazolines are micro-injected into the brainstem (Bousquet et al. 1984) . However, a number of brain regions were more abundantly enriched with I-sites than the RVLM, notably the inferior olive, pontine regions, and hypothalamus (Table 1) . Furthermore, our competition binding curves ( Figure 5 ) make it doubtful that the non-adrenergic site labeled by [ It should be noted that ␣ 2 AR would be nearly saturated at a concentration of 50 nM [ (Piletz et al. 1996) . On the other hand, I-sites would only be half-saturated (K D ϭ 55 nM for [ 125 I]p-iodoclonidine). Therefore, the proportions of these two sites in, for instance, the CA1 molecular layer might actually be re-estimated to be 6:5 for I-sites:␣ 2 AR. Using similar calculations, the CA4 region of the hippocampus might be estimated to possess a 9:3 ratio of I-sites:␣ 2 AR as labeled by [ a In these cases the non-linear regression fits were forced through y ϭ 0.
3 H]-MIDX (r 2 ϭ Ϫ 0.068) when comparing the densities of these two sites in human brain regions. This is a surprising difference from the positive correlation we observed (p ϭ .0003, r 2 ϭ 0.385) across 27 brain regions between these sites (Figure 2 ). However, of the eight brain regions in common between our two studies (cortical layers 1, 2-4, 5-6, hippocampal layer CA1, dentate gyrus, caudate putamen, raphe nuclei, Figure  2 ). This high affinity Ki value supports the candidacy of harmane as an endogenous I-site ligand (Hudson 1999) . Harmane has been reported to have high affinity for I 1 sites in filtration binding assays and to be active in modulating blood pressure in the CNS (Hudson 1999) . The other endogenous I-site ligand, agmatine, had no affinity whatsoever for I-sites in the present study. Little is known about the regional distribution of harmane in the brain, and future studies will be required to determine if it co-localizes with putative IR sites.
In summary, the distribution of a novel I-site for [ Angel and coworkers (1995) . It remains to be discovered what the function of this site is, but given the plethora of actions previously ascribed to clonidine (Buccafusco 1992) , it should be of interest to psychiatry. Currently, we are attempting to determine whether this is the same I-site that was reported previously to be decreased in the hippocampus of depressed suicide victims (Piletz et al. 2000b ) and increased in the frontal cortex of depressed suicide victims (Garcia-Sevilla et al. 1996) .
